⚡ Flash Summary

786 Investments Limited has successfully completed the subscription of a rights issue by its directors and a substantial shareholder, BRR Guardian Limited. A total of 2,322,018 right shares were subscribed at an exercise price of PKR 10 per share, raising PKR 23,220,180 for the company. This capital infusion, confirmed by an auditor’s certificate dated December 29, 2025, indicates strong insider commitment and strengthens the company’s equity base in compliance with regulatory requirements.

📌 Key Takeaways

• ✅ 786 Investments Limited secured PKR 23,220,180 through a rights issue.
• 📈 A total of 2,322,018 right shares were subscribed.
• 💰 The exercise price for these shares was PKR 10 per share.
• 🗓️ The subscription money was received on December 24, 2025.
• 👨‍💼 Directors and a substantial shareholder fully subscribed their entitlements.
• 🏢 Miss Tara Uzra Dawood, CEO, subscribed 1,492,166 shares for PKR 14,921,660.
• 🛡️ BRR Guardian Limited, a substantial shareholder, subscribed 824,854 shares for PKR 8,248,540.
• 📋 The auditor’s certificate, issued by M/s. Riaz Ahmad & Company, is dated December 29, 2025.
• 🔍 The transaction confirms compliance with Companies (Further Issue of Shares) Regulation, 2020.
• ⚖️ This move also meets Pakistan Stock Exchange (PSX) requirements for auditor certificates before trading commencement.
• 💪 Insider participation signals confidence in the company’s future prospects.
• Capital injection strengthens the company’s balance sheet by increasing equity.
• Dilution for existing shareholders who did not subscribe is implied, though the document doesn’t provide prior share count.

🎯 Investment Thesis

Given the limited information, which primarily confirms a successful rights issue subscribed by insiders, a ‘HOLD’ rating is appropriate. The positive signal from significant insider participation, including the CEO and a substantial shareholder, subscribing to their full entitlement at PKR 10 per share, indicates strong internal confidence in 786 Investments Limited’s future. This capital infusion strengthens the company’s equity base and improves its financial standing by PKR 23,220,180, which is a positive development. However, without access to full financial statements, performance trends, and future strategic plans, a definitive ‘BUY’ recommendation with a price target is not possible. Investors should maintain their positions and await further financial disclosures to gain a clearer picture of the company’s operational performance and long-term prospects before making aggressive investment decisions. A hypothetical price target would require detailed financial modeling that is not supported by the provided document. The current action represents a stable, albeit not immediately transformative, step.